Shots:

• Sangamo to receive $75M upfront within 30 days- $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally- Sangamo to take care of certain research and manufacturing activities funded by Novartis
• Novartis to get exclusive license rights of ZFP-TFs for three genes including ASD and intellectual disability for neurodevelopmental disorders also holds an option to license Sangamo’s AAVs. The company will perform research activities- investigational new drug-enabling studies clinical development- related regulatory interactions- manufacturing and- global commercialization
• ZFP-TFs is a genome regulation technology delivered using AAVs and will be utilized by the partnering companies to upregulate- or activate- the expression of genes expressed in individuals with certain types of neurodevelopmental disorders

Ref: Businesswire | Image: Novartis